- Home
- NET vs RMD Comparison
NET vs RMD Comparison
Compare NET & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NET
- RMD
- Stock Information
- Founded
- NET 2009
- RMD 1989
- Country
- NET United States
- RMD United States
- Employees
- NET N/A
- RMD N/A
- Industry
- NET Computer Software: Prepackaged Software
- RMD Medical/Dental Instruments
- Sector
- NET Technology
- RMD Health Care
- Exchange
- NET Nasdaq
- RMD Nasdaq
- Market Cap
- NET 63.7B
- RMD 36.7B
- IPO Year
- NET 2019
- RMD 1995
- Fundamental
- Price
- NET $194.74
- RMD $254.06
- Analyst Decision
- NET Buy
- RMD Buy
- Analyst Count
- NET 27
- RMD 12
- Target Price
- NET $142.19
- RMD $259.40
- AVG Volume (30 Days)
- NET 3.4M
- RMD 783.6K
- Earning Date
- NET 07-31-2025
- RMD 07-31-2025
- Dividend Yield
- NET N/A
- RMD 0.83%
- EPS Growth
- NET N/A
- RMD 37.08
- EPS
- NET N/A
- RMD 8.91
- Revenue
- NET $1,770,111,000.00
- RMD $5,021,529,000.00
- Revenue This Year
- NET $26.85
- RMD $10.37
- Revenue Next Year
- NET $26.49
- RMD $7.77
- P/E Ratio
- NET N/A
- RMD $28.80
- Revenue Growth
- NET 27.79
- RMD 9.54
- 52 Week Low
- NET $69.26
- RMD $188.56
- 52 Week High
- NET $198.01
- RMD $263.05
- Technical
- Relative Strength Index (RSI)
- NET 68.90
- RMD 53.77
- Support Level
- NET $187.77
- RMD $253.94
- Resistance Level
- NET $198.01
- RMD $259.49
- Average True Range (ATR)
- NET 6.17
- RMD 3.77
- MACD
- NET -0.73
- RMD -0.50
- Stochastic Oscillator
- NET 85.63
- RMD 41.96
About NET Cloudflare Inc.
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
About RMD ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.